Eupraxia Pharmaceuticals (EPRX) announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Sub-analyses of scores including at least 12 injections indicated that: at 12 weeks, 59% of patients achieved clinical remission; at 24 weeks, 76% of patients maintained clinical remission, and at 52 weeks, 67% of patients maintained clinical remission. At 24 weeks, dose cohort 9 showed a mean reduction of 4.0 points in SDI score where a reduction of 3.0 points is considered clinical remission. Comparison of histologic and symptom data from Cohort 8b versus Cohort 8 at 12 weeks demonstrated meaningfully improved outcomes due to improved drug delivery to the tissues associated with the appropriate catheter. No SAEs have been reported to date. EP-104GI has been well tolerated at all dose levels, including the highest dose of 8 mg/site.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Eupraxia price target lowered to $11 from $12 at H.C. Wainwright
- Buy Rating on Eupraxia Pharmaceuticals Driven by EP-104GI’s Differentiated Technology and Favorable Risk‑Reward Profile
- Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI Pipeline Create Attractive Risk‑Reward and Support Buy Rating
- Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing
- Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline